The Experts below are selected from a list of 170064 Experts worldwide ranked by ideXlab platform

Per Eystein Lonning - One of the best experts on this subject based on the ideXlab platform.

  • Influence of droloxifene on plasma levels of Insulin-Like Growth Factor (IGF)-I, Pro-IGF-IIE, Insulin-Like Growth Factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients.
    The Journal of steroid biochemistry and molecular biology, 1996
    Co-Authors: Svein Inge Helle, G B Anker, Michael Tally, K. Hall, Per Eystein Lonning
    Abstract:

    The influence of the novel anti-estrogen droloxifene on the Insulin-Like Growth Factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples were obtained from all patients before treatment and after 3 months (group 1) or 6 months (group 2) on droloxifene treatment, except for two patients in group 2 from whom the second sample was obtained following 2 months on treatment when the drug was to be terminated due to progressive disease. Insulin-Like Growth Factor (IGF)-I, Insulin-Like Growth Factor binding protein (IGFBP)-1, IGFBP-3 and pro-IGF-IIE (IGF-IIE) were measured by radioimmunoassay. In patients in group 1, plasma lGF-I levels decreased by a mean value of 20% (P < 0.05) on treatment with droloxifene, while IGFBP-1 increased by a mean value of 45% (P > 0.1). In group 2 we observed a 42% decrease in IGF-I during treatment (P < 0.025), while the level of IGFBP-1 increased by a mean value of 70% (P < 0.025). No significant effect on IGF-IIE or IGFBP-3 was noted in any of the groups. The change in plasma lGF-I and IGFBP-1 observed during treatment with droloxifene resembles what is found in patients treated with tamoxifen. As IGF-I is a potent mitogen for breast cancer cells in vitro, a decrease in the plasma level of this Growth Factor with an increase in the concentration of IGFBP-1 may contribute to the anti-tumour effects of droloxifene.

  • influence of droloxifene on plasma levels of insulin like Growth Factor igf i pro igf iie insulin like Growth Factor binding protein igfbp 1 and igfbp 3 in breast cancer patients
    The Journal of Steroid Biochemistry and Molecular Biology, 1996
    Co-Authors: Svein Inge Helle, G B Anker, Michael Tally, K. Hall, Per Eystein Lonning
    Abstract:

    The influence of the novel anti-estrogen droloxifene on the Insulin-Like Growth Factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples were obtained from all patients before treatment and after 3 months (group 1) or 6 months (group 2) on droloxifene treatment, except for two patients in group 2 from whom the second sample was obtained following 2 months on treatment when the drug was to be terminated due to progressive disease. Insulin-Like Growth Factor (IGF)-I, Insulin-Like Growth Factor binding protein (IGFBP)-1, IGFBP-3 and pro-IGF-IIE (IGF-IIE) were measured by radioimmunoassay. In patients in group 1, plasma IGF-I levels decreased by a mean value of 20% (P 0.1). In group 2 we observed a 42% decrease in IGF-I during treatment (P < 0.025), while the level of IGFBP-1 increased by a mean value of 70% (P < 0.025). No significant effect on IGF-IIE or IGFBP-3 was noted in any of the groups. The change in plasma IGF-I and IGFBP-1 observed during treatment with droloxifene resembles what is found in patients treated with tamoxifen. As IGF-I is a potent mitogen for breast cancer cells in vitro, a decrease in the plasma level of this Growth Factor with an increase in the concentration of IGFBP-1 may contribute to the anti-tumour effects of droloxifene.

Geoffrey Goldspink - One of the best experts on this subject based on the ideXlab platform.

  • Insulin-Like Growth Factor–1 gene splice variants as markers of muscle damage in levator ani muscle after the first vaginal delivery
    American Journal of Obstetrics and Gynecology, 2005
    Co-Authors: Eduardo Cortes, Lan F. Wong Te Fong, M Hameed, Stephen D. R. Harridge, Allan B. Maclean, Shi Yu Yang, Wendy M.n. Reid, Geoffrey Goldspink
    Abstract:

    Objective Studies in animals and human muscle have demonstrated differential splicing of the Insulin-Like Growth Factor–1 gene in response to mechanical strain and damage. We conducted a study on the expression of Insulin-Like Growth Factor–1 splice variants in the levator ani muscle after the first vaginal delivery. Study design Ten women were recruited after the first vaginal delivery. Biopsy specimens were taken vaginally of the pubovisceral component of the levator ani muscle. Five nonpregnant women were recruited as control subjects. Samples were processed with real-time quantitative polymerase chain reaction, with specific primers for the Insulin-Like Growth Factor–1 splice variants. Results Insulin-Like Growth Factor splice variants mechano Growth Factor and Insulin-Like Growth Factor–1Ea were significantly up-regulated (100- and 1000-fold) in the delivery population, compared with control subjects ( P =.012 and .04, respectively). Statistical analysis indicated a correlation between the expression of the Insulin-Like Growth Factor–1 splice variants and the length of the second stage. Conclusion These results show that damaged levator ani muscle results from stretch and overload after the first vaginal delivery.

  • insulin like Growth Factor 1 gene splice variants as markers of muscle damage in levator ani muscle after the first vaginal delivery
    American Journal of Obstetrics and Gynecology, 2005
    Co-Authors: Eduardo Cortes, M Hameed, Stephen D. R. Harridge, Allan B. Maclean, Shi Yu Yang, Wendy M.n. Reid, Lan Wong Te F Fong, Geoffrey Goldspink
    Abstract:

    Objective Studies in animals and human muscle have demonstrated differential splicing of the Insulin-Like Growth Factor–1 gene in response to mechanical strain and damage. We conducted a study on the expression of Insulin-Like Growth Factor–1 splice variants in the levator ani muscle after the first vaginal delivery. Study design Ten women were recruited after the first vaginal delivery. Biopsy specimens were taken vaginally of the pubovisceral component of the levator ani muscle. Five nonpregnant women were recruited as control subjects. Samples were processed with real-time quantitative polymerase chain reaction, with specific primers for the Insulin-Like Growth Factor–1 splice variants. Results Insulin-Like Growth Factor splice variants mechano Growth Factor and Insulin-Like Growth Factor–1Ea were significantly up-regulated (100- and 1000-fold) in the delivery population, compared with control subjects ( P =.012 and .04, respectively). Statistical analysis indicated a correlation between the expression of the Insulin-Like Growth Factor–1 splice variants and the length of the second stage. Conclusion These results show that damaged levator ani muscle results from stretch and overload after the first vaginal delivery.

Svein Inge Helle - One of the best experts on this subject based on the ideXlab platform.

  • Influence of droloxifene on plasma levels of Insulin-Like Growth Factor (IGF)-I, Pro-IGF-IIE, Insulin-Like Growth Factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients.
    The Journal of steroid biochemistry and molecular biology, 1996
    Co-Authors: Svein Inge Helle, G B Anker, Michael Tally, K. Hall, Per Eystein Lonning
    Abstract:

    The influence of the novel anti-estrogen droloxifene on the Insulin-Like Growth Factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples were obtained from all patients before treatment and after 3 months (group 1) or 6 months (group 2) on droloxifene treatment, except for two patients in group 2 from whom the second sample was obtained following 2 months on treatment when the drug was to be terminated due to progressive disease. Insulin-Like Growth Factor (IGF)-I, Insulin-Like Growth Factor binding protein (IGFBP)-1, IGFBP-3 and pro-IGF-IIE (IGF-IIE) were measured by radioimmunoassay. In patients in group 1, plasma lGF-I levels decreased by a mean value of 20% (P < 0.05) on treatment with droloxifene, while IGFBP-1 increased by a mean value of 45% (P > 0.1). In group 2 we observed a 42% decrease in IGF-I during treatment (P < 0.025), while the level of IGFBP-1 increased by a mean value of 70% (P < 0.025). No significant effect on IGF-IIE or IGFBP-3 was noted in any of the groups. The change in plasma lGF-I and IGFBP-1 observed during treatment with droloxifene resembles what is found in patients treated with tamoxifen. As IGF-I is a potent mitogen for breast cancer cells in vitro, a decrease in the plasma level of this Growth Factor with an increase in the concentration of IGFBP-1 may contribute to the anti-tumour effects of droloxifene.

  • influence of droloxifene on plasma levels of insulin like Growth Factor igf i pro igf iie insulin like Growth Factor binding protein igfbp 1 and igfbp 3 in breast cancer patients
    The Journal of Steroid Biochemistry and Molecular Biology, 1996
    Co-Authors: Svein Inge Helle, G B Anker, Michael Tally, K. Hall, Per Eystein Lonning
    Abstract:

    The influence of the novel anti-estrogen droloxifene on the Insulin-Like Growth Factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples were obtained from all patients before treatment and after 3 months (group 1) or 6 months (group 2) on droloxifene treatment, except for two patients in group 2 from whom the second sample was obtained following 2 months on treatment when the drug was to be terminated due to progressive disease. Insulin-Like Growth Factor (IGF)-I, Insulin-Like Growth Factor binding protein (IGFBP)-1, IGFBP-3 and pro-IGF-IIE (IGF-IIE) were measured by radioimmunoassay. In patients in group 1, plasma IGF-I levels decreased by a mean value of 20% (P 0.1). In group 2 we observed a 42% decrease in IGF-I during treatment (P < 0.025), while the level of IGFBP-1 increased by a mean value of 70% (P < 0.025). No significant effect on IGF-IIE or IGFBP-3 was noted in any of the groups. The change in plasma IGF-I and IGFBP-1 observed during treatment with droloxifene resembles what is found in patients treated with tamoxifen. As IGF-I is a potent mitogen for breast cancer cells in vitro, a decrease in the plasma level of this Growth Factor with an increase in the concentration of IGFBP-1 may contribute to the anti-tumour effects of droloxifene.

Eduardo Cortes - One of the best experts on this subject based on the ideXlab platform.

  • Insulin-Like Growth Factor–1 gene splice variants as markers of muscle damage in levator ani muscle after the first vaginal delivery
    American Journal of Obstetrics and Gynecology, 2005
    Co-Authors: Eduardo Cortes, Lan F. Wong Te Fong, M Hameed, Stephen D. R. Harridge, Allan B. Maclean, Shi Yu Yang, Wendy M.n. Reid, Geoffrey Goldspink
    Abstract:

    Objective Studies in animals and human muscle have demonstrated differential splicing of the Insulin-Like Growth Factor–1 gene in response to mechanical strain and damage. We conducted a study on the expression of Insulin-Like Growth Factor–1 splice variants in the levator ani muscle after the first vaginal delivery. Study design Ten women were recruited after the first vaginal delivery. Biopsy specimens were taken vaginally of the pubovisceral component of the levator ani muscle. Five nonpregnant women were recruited as control subjects. Samples were processed with real-time quantitative polymerase chain reaction, with specific primers for the Insulin-Like Growth Factor–1 splice variants. Results Insulin-Like Growth Factor splice variants mechano Growth Factor and Insulin-Like Growth Factor–1Ea were significantly up-regulated (100- and 1000-fold) in the delivery population, compared with control subjects ( P =.012 and .04, respectively). Statistical analysis indicated a correlation between the expression of the Insulin-Like Growth Factor–1 splice variants and the length of the second stage. Conclusion These results show that damaged levator ani muscle results from stretch and overload after the first vaginal delivery.

  • insulin like Growth Factor 1 gene splice variants as markers of muscle damage in levator ani muscle after the first vaginal delivery
    American Journal of Obstetrics and Gynecology, 2005
    Co-Authors: Eduardo Cortes, M Hameed, Stephen D. R. Harridge, Allan B. Maclean, Shi Yu Yang, Wendy M.n. Reid, Lan Wong Te F Fong, Geoffrey Goldspink
    Abstract:

    Objective Studies in animals and human muscle have demonstrated differential splicing of the Insulin-Like Growth Factor–1 gene in response to mechanical strain and damage. We conducted a study on the expression of Insulin-Like Growth Factor–1 splice variants in the levator ani muscle after the first vaginal delivery. Study design Ten women were recruited after the first vaginal delivery. Biopsy specimens were taken vaginally of the pubovisceral component of the levator ani muscle. Five nonpregnant women were recruited as control subjects. Samples were processed with real-time quantitative polymerase chain reaction, with specific primers for the Insulin-Like Growth Factor–1 splice variants. Results Insulin-Like Growth Factor splice variants mechano Growth Factor and Insulin-Like Growth Factor–1Ea were significantly up-regulated (100- and 1000-fold) in the delivery population, compared with control subjects ( P =.012 and .04, respectively). Statistical analysis indicated a correlation between the expression of the Insulin-Like Growth Factor–1 splice variants and the length of the second stage. Conclusion These results show that damaged levator ani muscle results from stretch and overload after the first vaginal delivery.

G B Anker - One of the best experts on this subject based on the ideXlab platform.

  • Influence of droloxifene on plasma levels of Insulin-Like Growth Factor (IGF)-I, Pro-IGF-IIE, Insulin-Like Growth Factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients.
    The Journal of steroid biochemistry and molecular biology, 1996
    Co-Authors: Svein Inge Helle, G B Anker, Michael Tally, K. Hall, Per Eystein Lonning
    Abstract:

    The influence of the novel anti-estrogen droloxifene on the Insulin-Like Growth Factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples were obtained from all patients before treatment and after 3 months (group 1) or 6 months (group 2) on droloxifene treatment, except for two patients in group 2 from whom the second sample was obtained following 2 months on treatment when the drug was to be terminated due to progressive disease. Insulin-Like Growth Factor (IGF)-I, Insulin-Like Growth Factor binding protein (IGFBP)-1, IGFBP-3 and pro-IGF-IIE (IGF-IIE) were measured by radioimmunoassay. In patients in group 1, plasma lGF-I levels decreased by a mean value of 20% (P < 0.05) on treatment with droloxifene, while IGFBP-1 increased by a mean value of 45% (P > 0.1). In group 2 we observed a 42% decrease in IGF-I during treatment (P < 0.025), while the level of IGFBP-1 increased by a mean value of 70% (P < 0.025). No significant effect on IGF-IIE or IGFBP-3 was noted in any of the groups. The change in plasma lGF-I and IGFBP-1 observed during treatment with droloxifene resembles what is found in patients treated with tamoxifen. As IGF-I is a potent mitogen for breast cancer cells in vitro, a decrease in the plasma level of this Growth Factor with an increase in the concentration of IGFBP-1 may contribute to the anti-tumour effects of droloxifene.

  • influence of droloxifene on plasma levels of insulin like Growth Factor igf i pro igf iie insulin like Growth Factor binding protein igfbp 1 and igfbp 3 in breast cancer patients
    The Journal of Steroid Biochemistry and Molecular Biology, 1996
    Co-Authors: Svein Inge Helle, G B Anker, Michael Tally, K. Hall, Per Eystein Lonning
    Abstract:

    The influence of the novel anti-estrogen droloxifene on the Insulin-Like Growth Factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples were obtained from all patients before treatment and after 3 months (group 1) or 6 months (group 2) on droloxifene treatment, except for two patients in group 2 from whom the second sample was obtained following 2 months on treatment when the drug was to be terminated due to progressive disease. Insulin-Like Growth Factor (IGF)-I, Insulin-Like Growth Factor binding protein (IGFBP)-1, IGFBP-3 and pro-IGF-IIE (IGF-IIE) were measured by radioimmunoassay. In patients in group 1, plasma IGF-I levels decreased by a mean value of 20% (P 0.1). In group 2 we observed a 42% decrease in IGF-I during treatment (P < 0.025), while the level of IGFBP-1 increased by a mean value of 70% (P < 0.025). No significant effect on IGF-IIE or IGFBP-3 was noted in any of the groups. The change in plasma IGF-I and IGFBP-1 observed during treatment with droloxifene resembles what is found in patients treated with tamoxifen. As IGF-I is a potent mitogen for breast cancer cells in vitro, a decrease in the plasma level of this Growth Factor with an increase in the concentration of IGFBP-1 may contribute to the anti-tumour effects of droloxifene.